Venture Visionary Partners LLC lifted its position in shares of Danaher Corporation (NYSE:DHR – Free Report) by 181.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,039 shares of the conglomerate’s stock after acquiring an additional 16,784 shares during the quarter. Venture Visionary Partners LLC’s holdings in Danaher were worth $5,769,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in DHR. BlackRock Inc. bought a new stake in Danaher during the 2nd quarter worth about $10,492,520,000. Jupiter Topco LLC bought a new position in shares of Danaher in the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher during the 2nd quarter worth approximately $1,287,949,000. Bank of America Corp DE bought a new stake in shares of Danaher during the second quarter worth approximately $993,846,000. Finally, Legal & General Group Plc acquired a new position in Danaher in the second quarter valued at approximately $801,056,000. Institutional investors own 79.05% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have commented on DHR shares. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Piper Sandler began coverage on Danaher in a research report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target on the stock. Barclays lifted their price objective on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Finally, Evercore restated an “outperform” rating and set a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.23.
Danaher Stock Up 1.5%
Shares of DHR traded up $3.24 on Wednesday, hitting $218.85. The company’s stock had a trading volume of 3,974,091 shares, compared to its average volume of 4,460,003. The firm’s fifty day moving average price is $210.46 and its 200-day moving average price is $194.25. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $153.85 billion, a price-to-earnings ratio of 38.87, a P/E/G ratio of 2.75 and a beta of 0.76.
Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period last year, the company posted $0.77 EPS. On average, equities research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.
Danaher Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.
The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.
Further Reading
- Five stocks we like better than Danaher
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
